Leukaemia gene provides clue to treating triple negative breast cancer

Cancer Research UK

Cancer Research UK scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with ‘triple negative’ breast cancer, according to a study published in PLOS ONE, today (Thursday).

The team of researchers at the Cancer Research UK Beatson Institute and University of Glasgow, measured levels of a protein produced by the RUNX1 gene in tumour samples from 483 patients with a range of breast cancer types*.

They found that patients with triple negative breast cancer who had the RUNX1 protein in their cells had poorer survival compared to those without the RUNX1 protein.

Of the 118 patients with triple-negative breast cancer, those who tested positive for the RUNX1 protein were around four times more likely to die from their cancer in the follow-up period – around 14 years on average – than those without it.

And the faulty gene could provide a target for the development of new drugs to treat the disease as well.

Every year between 4,800 and 16,100 women are diagnosed with triple negative breast cancer in the UK**.

The disease is often hard to treat as the cancer cells do not contain receptors for the hormones oestrogen or progesterone – targeted by hormone therapies such as tamoxifen – or receptors for the protein HER2, treatable with Herceptin.

RUNX1 plays an important role in controlling cell development and is one of the most commonly altered genes in leukaemia. But this is the first time it has been implicated in triple negative breast cancer.

Study author, Dr Karen Blyth, at the Cancer Research UK Beatson Institute and University of Glasgow, said: “Because levels of RUNX1 appear to be linked to triple negative breast cancers, this opens up the exciting possibility of using it as a new target for treatments.

“Now we’ve got to prove this early research in larger studies and pin down exactly what’s happening in these cells, to understand how this protein behaves in triple negative breast cancer tumours.”

Dr Kat Arney, Cancer Research UK’s science communications manager, said: “There’s still so much we need to understand about triple negative breast cancers, as they can be harder to treat in some people.

“Almost two out of three women with breast cancer now survive their disease beyond 20 years. But more must be done and we urgently need more studies like these, particularly in lesser-understood forms of the disease, to build on the progress we’ve already made and save more lives.”

ENDS

For media enquiries please contact the press office on 020 3469 8300 or, out-of-hours, the duty press officer on 07050 264 059.

References

Ferrari, N et al. Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer (2014) PLOS ONE.

Notes to Editor

*All patients had invasive ductal breast cancer – which accounts for around 90 per cent of all invasive breast cancers.

**It is estimated that in England between 10 per cent and 32 per cent of breast cancers in women are hormone receptor triple negative. Source: National Cancer Intelligence Network (2009). All Breast Cancer Report http://www.ncin.org.uk/view?rid=68. These figures have been applied to the number of women diagnosed with breast cancer (ICD-10 C50) in the UK in 2011. Around 49,900 women and around 350 men in the UK are diagnosed with invasive breast cancer in the UK, every year.  And there are around 11,700 female and around 80 male deaths from invasive breast cancer every year.